

Adult Vaccine Market, Global Analysis By Disease (Influenza, Cervical Cancer, Zoster, MMR , Pneumonia, Meningitis, Hepatitis, Tap , Varicella & Travel & Miscellaneous Vaccine) & Companies

<https://marketpublishers.com/r/AE406474432EN.html>

Date: July 2018

Pages: 0

Price: US\$ 1,690.00 (Single User License)

ID: AE406474432EN

Abstracts

Adult Vaccine Market is projected to reach US\$ 22 Billion by the year 2024. Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable diseases. Several organizations such as Global Immunization Vision and Strategy (GIVS), WHO's Global Vaccine Action Plan, The GAVI Alliance are putting their best to reduce the occurrence of vaccine-preventable diseases around the world which certainly is driving the adult vaccine market sturdily.

Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period.

Renub Research report titled "Adult Vaccine Market, Global Analysis By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella and Travel & Miscellaneous Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)" provides a complete analysis of Global Adults Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at noteworthy rate over the

coming years

The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella, and Travel & Miscellaneous Vaccine. Pneumococcal and Hepatitis together hold the significant market share in global adult vaccine market and is expected to continue so in the forecast period.

By End User – Global Adults Vaccine Market

The report studies the market by end user as Adults. Around the world, thousands of adults become seriously ill, get hospitalized and even die because of diseases that vaccines can help prevent. By getting vaccinated, one can help protect themselves from much of this needless suffering.

Almost 350 Million Adults get vaccinated by 2024

Due to the increasing prevalence of diseases and growing awareness regarding the vaccine-preventable diseases, it is estimated that by the year 2024, nearly 350 million adults get vaccinated; in order to protect themselves from diseases. Some of the vaccines which hold considerable share in terms of adult vaccination include Influenza, Hepatitis, HPV and Pneumonia vaccine.

Regional - Immunization Profile

The report also studies the Immunization profile around the world; By Disease - Measles, Mumps, Rubella, Japanese encephalitis, Tetanus, Pertussis, Yellow Fever. While By Regions, it studies Americas (AMR), Europe (EUR), Africa (AFR), Eastern Mediterranean (EMR), South-East Asia (SEAR), Western Pacific (WPR) and Global.

Company Analysis

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.

Global Adults Vaccine Market has been extensively studied from 3 major points:

1. Adult Vaccines (Disease wise) Market & Forecast

2. Number of Vaccinated Adults (Disease wise) & Forecast
3. Doses of Vaccines Administered in Adults(Disease wise) & Forecast

By Disease

Influenza

Cervical Cancer

Zoster (Shingles)

MMR (Measles, Mumps, and Rubella)

Pneumonia

Meningitis

Hepatitis

Tap (Diphtheria, Tetanus, Pertussis)

Varicella

Travel & Miscellaneous Vaccine

Key Companies Covered in the Report

GlaxoSmithKline

Merck

Sanofi

Pfizer

Contents

1. RESEARCH FINDINGS

2. ADULT VACCINES MARKET (2011 – 2024)

3. MARKET & NUMBERS SHARE - ADULT VACCINES

- 3.1 Adult Vaccine Market Share
- 3.2 Adult Vaccinated Population Share
- 3.3 Adult Doses of Vaccines Administered Share
- 3.4 Vaccine Companies Market Share

4. ADULT VACCINATED NUMBERS

5. ADULT DOSES OF VACCINES ADMINISTERED

6. DISEASE WISE – ADULT VACCINES MARKET (2011 – 2024)

- 6.1 Influenza
- 6.2 Cervical Cancer (HPV)
- 6.3 Zoster (Shingles)
- 6.4 MMR (Measles, Mumps, and Rubella Vaccine)
- 6.5 Pneumococcal
- 6.6 Meningococcal
- 6.7 Hepatitis
- 6.8 TdaP
- 6.9 Travel and Miscellaneous
- 6.10 Varicella

7. DISEASE WISE – NUMBERS OF VACCINATED ADULTS (2011 – 2024)

- 7.1 Influenza
- 7.2 Cervical Cancer (HPV)
- 7.3 Zoster (Shingles)
- 7.4 MMR
- 7.5 Pneumococcal
- 7.6 Meningococcal
- 7.7 Hepatitis

7.8 TdaP

7.9 Varicella

8. DISEASE WISE – DOSES OF VACCINES ADMINISTERED IN ADULTS (2011 – 2024)

8.1 Influenza

8.2 Cervical Cancer (HPV)

8.3 Zoster (Shingles)

8.4 MMR

8.5 Pneumococcal

8.6 Meningococcal

8.7 Hepatitis

8.8 TdaP

8.9 Varicella

9. DISEASE WISE - IMMUNIZATION PROFILE

9.1 Immunization Coverage (%) in Infants

9.2 Global Immunization Profile

9.3 By Geographic Region – Immunization Profile

9.3.1 Measles – Number of Reported Cases

9.3.2 Mumps – Number of Reported Cases

9.3.3 Rubella – Number of Reported Cases

9.3.4 Rubella (CRS) – Number of Reported Cases

9.3.5 Diphtheria – Number of Reported Cases

9.3.6 Tetanus (Neonatal) – Number of Reported Cases

9.3.7 Tetanus (Total) – Number of Reported Cases

9.3.8 Pertussis – Number of Reported Cases

9.3.9 Polio – Number of Reported Cases

9.3.10 Yellow Fever – Number of Reported Cases

9.3.11 Japanese encephalitis – Number of Reported Cases

10. VACCINES KEY PLAYERS SALES (2011 – 2024)

10.1 GlaxoSmithKline, plc.'s Vaccines Sales

10.2 Merck & Co. Vaccines Sales

10.3 Sanofi Pasteur's Vaccines Sales

10.4 Pfizer, Inc.'s Vaccines Sales

10.5 Global – Other Companies Vaccines Sales

11. VACCINES – PRODUCTS AND PIPELINE

- 11.1 GSK Vaccine Product Pipeline
- 11.2 Merck Vaccine Product Pipeline
- 11.3 Sanofi Vaccine Product Pipeline
- 11.4 Pfizer Vaccine Product Pipeline

12. TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY

13. VACCINES AND REGULATOR’S INTERVENTIONS

- 13.1 Making and Meeting Standards of Quality and Safety
- 13.2 Vaccine Funding

14. VACCINE MARKET DRIVERS

- 14.1 Inclusion in National Immunization Schedule
- 14.2 Growing Immunization Coverage for HPV Vaccines
- 14.3 Increase in Prevalence of Infectious Diseases
- 14.4 Global Immunization Vision and Strategy (GIVS)
- 14.5 GAVI Model Fuelling Vaccine Manufacturers
 - 14.5.1 The Partnership Model
 - 14.5.2 The Business Model
- 14.6 Increasing Vaccine Availability in United States
- 14.7 The Vaccine Safety Data link Project
- 14.8 The Vaccine Injury Compensation Program
- 14.9 Transforming of Vaccine Technologies
- 14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
- 14.11 Continuous Focus on Effective Communication Strategies

15. VACCINES MARKET CHALLENGES

- 15.1 Hurdles to Optimal use of Licensed Vaccines
 - 15.1.1 Technical Obstacles
 - 15.1.2 Economic Obstacles
 - 15.1.3 Cultural Obstacles
- 15.2 Complexity of Vaccine Development & Approval System Thwarts Product

Development

15.2.1 Legal Obstacles

15.2.2 General Technical Barriers

15.2.3 Economic Barriers

15.2.4 Regulatory Barriers

15.3 Shortening the Timeline for Vaccine Development

15.4 Refusal/Resistance to Vaccination

15.4.1 Vaccine Adverse Event Reporting System

15.5 Vaccine Shortages and Delays

15.6 Obstacles in Vaccine Research & Development

15.7 Barriers to New Entrants in the Vaccines Market

List Of Figures

LIST OF FIGURES

- Figure 2-1: Global – Adult Vaccines Market (Billion US\$), 2011 – 2017
- Figure 2-2: Global – Forecast for Adult Vaccines Market (Billion US\$), 2018 – 2024
- Figure 3-1: Global – Adult Vaccines Market Share (Percent), 2011 - 2017
- Figure 3-2: Global – Forecast for Adult Vaccines Market Share (Percent), 2018 - 2024
- Figure 3-3: Global – Vaccinated Adult Share (Percent), 2011 - 2017
- Figure 3-4: Global – Forecast for Vaccinated Adult Share (Percent), 2018 – 2024
- Figure 3-5: Global – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2017
- Figure 3-6: Global – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2018 - 2024
- Figure 3-7: Global – Key Players Vaccines Market Share (Percent), 2011 - 2017
- Figure 3-8: Global – Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
- Figure 4-1: Global – Number of Vaccinated Adult (Million), 2011 – 2017
- Figure 4-2: Global – Forecast for Number of Vaccinated Adult (Million), 2018 – 2024
- Figure 5-1: Global – Doses of Adult Vaccines Administered (Million), 2011 - 2017
- Figure 5-2: Global – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
- Figure 6-1: Influenza – Adult Vaccines Market (Billion US\$), 2011 - 2017
- Figure 6-2: Influenza – Forecast for Adult Vaccines Market (Billion US\$), 2018 – 2024
- Figure 6-3: Cervical Cancer (HPV) – Vaccines Market (Billion US\$), 2011 – 2017
- Figure 6-4: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US\$), 2018 - 2024
- Figure 6-5: Zoster (Shingles) – Vaccines Market (Billion US\$), 2011 - 2017
- Figure 6-6: Zoster (Shingles) – Forecast for Vaccines Market (Billion US\$), 2018 - 2024
- Figure 6-7: MMR – Adult Vaccines Market (Million US\$), 2011 – 2017
- Figure 6-8: MMR – Forecast for Adult Vaccines Market (Million US\$), 2018 – 2024
- Figure 6-9: Pneumococcal – Adult Vaccines Market (Billion US\$), 2011 - 2017
- Figure 6-10: Pneumococcal – Forecast for Adult Vaccines Market (Billion US\$), 2018 – 2024
- Figure 6-11: Areas with frequent epidemics of meningococcal meningitis
- Figure 6-12: Meningococcal – Adult Vaccines Market (Million US\$), 2011 – 2017
- Figure 6-13: Meningococcal – Forecast for Adult Vaccines Market (Million US\$), 2018 - 2024
- Figure 6-14: Hepatitis – Adult Vaccines Market (Billion US\$), 2011 - 2017

Figure 6-15: Hepatitis – Forecast for Adult Vaccines Market (Billion US\$), 2018 - 2024

Figure 6-16: Tdap – Adult Vaccines Market (Million US\$), 2011 - 2017

Figure 6-17: Tdap – Forecast for Adult Vaccines Market (Million US\$), 2018 - 2024

Figure 6-18: Travel and Miscellaneous – Vaccines Market (Billion US\$), 2011 - 2017

Figure 6-19: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US\$), 2018 - 2024

Figure 6-20: Varicella – Adult Vaccines Market (Million US\$), 2011 - 2017

Figure 6-21: Varicella – Forecast for Adult Vaccines Market (Million US\$), 2018 - 2024

Figure 7-1: Influenza – Number of Vaccinated Adults (Million), 2011 - 2017

Figure 7-2: Influenza – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024

Figure 7-3: Cervical Cancer – Number of Vaccinated People (Million), 2011 - 2017

Figure 7-4: Cervical Cancer – Forecast for Number of Vaccinated People (Million), 2018 - 2024

Figure 7-5: Zoster (Shingles) – Number of Vaccinated People (Million), 2011 - 2017

Figure 7-6: Zoster (Shingles) – Forecast for Number of Vaccinated People (Million), 2018 - 2024

Figure 7-7: MMR – Number of Vaccinated Adults (Million), 2011 - 2017

Figure 7-8: MMR – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024

Figure 7-9: Pneumococcal – Number of Vaccinated Adults (Million), 2011 - 2017

Figure 7-10: Pneumococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024

Figure 7-11: Meningococcal – Number of Vaccinated Adults (Million), 2011 - 2017

Figure 7-12: Meningococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024

Figure 7-13: Hepatitis – Number of Vaccinated Adults (Million), 2011 - 2017

Figure 7-14: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2018 - 2024

Figure 7-15: Tdap – Number of Vaccinated Adults (Million), 2011 - 2017

Figure 7-16: Tdap – Number of Vaccinated Adults (Million), 2018 - 2024

Figure 7-17: Varicella – Number of Vaccinated Adults (Million), 2011 - 2017

Figure 7-18: Varicella – Number of Vaccinated Adults (Million), 2018 - 2024

Figure 8-1: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2017

Figure 8-2: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024

Figure 8-3: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2017

Figure 8-4: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024

Figure 8-5: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2017

Figure 8-6: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024

Figure 8-7: MMR – Doses of Adult Vaccines Administered (Million), 2011 - 2017

Figure 8-8: MMR – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024

Figure 8-9: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017

Figure 8-10: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024

Figure 8-11: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017

Figure 8-12: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024

Figure 8-13: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2017

Figure 8-14: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024

Figure 8-15: Tdap – Doses of Adult Vaccines Administered (Million), 2011 - 2017

Figure 8-16: Tdap – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024

Figure 8-17: Varicella – Doses of Adult Vaccines Administered (Million), 2011 - 2017

Figure 8-18: Varicella – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024

Figure 10-1: Global - GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-2: Global – Forecast for GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-3: Global - Merck & Co. Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-4: Global – Forecast for Merck & Co. Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-5: Global - Sanofi Pasteur's Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-6: Global – Forecast for Sanofi Pasteur's Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-7: Global - Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-8: Global – Forecast for Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-9: Global – Other Companies Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-10: Global – Forecast for Other Companies Vaccines Sales (Billion US\$), 2018 - 2024

Figure 11-1: GSK Vaccine Product Pipeline

Figure 14-1: Countries with HPV Vaccination Program listed on their National

Immunization Program (NIP) Schedule

Figure 14-2: Number of Cases of Diphtheria, Pertussis, Tetanus & Measles by Major Region Worldwide, 2013

Figure 14-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 14-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 14-5: US Retail Clinics Expected to Surge by 2017

List Of Tables

LIST OF TABLES

- Table 2-1: Vaccine Recommendations
- Table 2-2: Other Recommended Vaccines
- Table 9-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
- Table 9-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
- Table 9-3: Vaccines – Number of Reported Cases, 2011 – 2017
- Table 9-4: Measles – Number of Reported Cases, 2001 – 2016
- Table 9-5: Mumps – Number of Reported Cases, 2001 - 2016
- Table 9-6: Rubella – Number of Reported Cases, 2001 - 2016
- Table 9-7: Rubella (CRS) – Number of Reported Cases, 2001 - 2016
- Table 9-8: Diphtheria – Number of Reported Cases, 2001 - 2016
- Table 9-9: Tetanus (Neonatal) – Number of Reported Cases, 2001 – 2016
- Table 9-10: Tetanus (Total) – Number of Reported Cases, 2001 - 2016
- Table 9-11: Pertussis – Number of Reported Cases, 2001 - 2016
- Table 9-12: Polio – Number of Reported Cases, 2001 - 2016
- Table 9-13: Yellow Fever – Number of Reported Cases, 2001 - 2016
- Table 9-14: Japanese Encephalitis – Number of Reported Cases Reported, 2006 - 2016
- Table 11-1: Merck Vaccine Product Pipeline
- Table 11-2: Sanofi Vaccine Product Pipeline
- Table 11-3: Pfizer Vaccine Product Pipeline
- Table 12-1: Vaccine Mergers & Acquisitions
- Table 14-1: United States Immunization Schedule
- Table 14-2: Afghanistan Immunization Schedule
- Table 14-3: Norway Immunization Schedule
- Table 14-4: India Immunization Schedule
- Table 14-5: Vietnam Immunization Schedule
- Table 14-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
- Table 14-7: Goal-Level Indicators, 2015 & 2020
- Table 14-8: Improvement Strategies or Requirements – the Joint Commission and the Project's Collaborating Organizations

I would like to order

Product name: Adult Vaccine Market, Global Analysis By Disease (Influenza, Cervical Cancer, Zoster, MMR , Pneumonia, Meningitis, Hepatitis, Tap , Varicella & Travel & Miscellaneous Vaccine) & Companies

Product link: <https://marketpublishers.com/r/AE406474432EN.html>

Price: US\$ 1,690.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AE406474432EN.html>